Skip to main content

Table 3 Cox proportional hazards regression models examining the prognostic value of clinical factors and signatures derived from single proteins and apoptosis modelling

From: System-based approaches as prognostic tools for glioblastoma

PredictorsHR95% CIP
Age (continuous, n = 46)1.021.00–1.050.06
Sex (ref. M, n = 24)  0.40
 F (n = 22)0.760.41–1.43 
Location (ref. left side, n = 13)  0.58
 Right side (n = 28)1.280.62–2.64 
 Other (n = 4)0.730.20–2.66 
History (ref. newly-diagnosed - no treatment, n = 31)  0.06
 Recurrent - no treatment (n = 6)1.860.69–5.01 
 Recurrent - treatment (n = 9)2.731.19–6.25 
MGMT promoter methylation (ref. methylated, n = 17)  0.52
 Unmethylated (n = 22)1.260.62–2.59 
Apaf-1 (ref. >median, n = 23)  0.20
 ≤ median (n = 23)1.520.80–2.87 
Procaspase-3 (ref. >median, n = 23)  0.06
 ≤ median (n = 23)1.910.99–3.69 
Procaspase-9 (ref. >median, n = 23)  0.49
 ≤ median (n = 23)1.250.66–2.37 
SMAC (ref. >median, n = 23)  0.38
 ≤ median (n = 23)1.340.70–2.55 
XIAP (ref. >median, n = 23)  0.47
 ≤ median (n = 23)1.270.67–2.40 
Apoptosis susceptibility (ref. SC > 80%, n = 37)  0.001
 SC ≤ 80% (n = 9)5.022.04–12.33 
Adjusted apoptosis susceptibility (ref. SC > 80%, n = 37)a  0.006
 SC ≤ 80% (n = 9)4.401.59–12.14 
  1. P-values determined by likelihood ratio tests
  2. aAdjusted for age, history and MGMT promoter status